Published in Public Health Rep on August 28, 2002
Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36
Ethics in public health research: protecting human subjects: the role of community advisory boards. Am J Public Health (2004) 3.08
Broadening participation in community problem solving: a multidisciplinary model to support collaborative practice and research. J Urban Health (2003) 2.94
Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health (2006) 2.20
From personal survival to public health: community leadership by men who have sex with men in the response to HIV. Lancet (2012) 1.75
Community advisory boards in community-based participatory research: a synthesis of best processes. Prev Chronic Dis (2011) 1.72
Project VIVA: a multilevel community-based intervention to increase influenza vaccination rates among hard-to-reach populations in New York City. Am J Public Health (2008) 1.18
Harlem service providers' perceptions of the impact of municipal policies on their clients with substance use problems. J Urban Health (2004) 1.06
A community-based approach to linking injection drug users with needed services through pharmacies: an evaluation of a pilot intervention in New York City. AIDS Educ Prev (2010) 1.02
Factors associated with differential uptake of seasonal influenza immunizations among underserved communities during the 2009-2010 influenza season. J Community Health (2012) 0.97
Involving local health departments in community health partnerships: evaluation results from the partnership for the public's health initiative. J Urban Health (2008) 0.96
The role of Community Advisory Boards (CABs) in Project Eban. J Acquir Immune Defic Syndr (2008) 0.94
Modeling the Structure of Partnership Between Researchers and Front-Line Service Providers: Strengthening Collaborative Public Health Research. J Mix Methods Res (2014) 0.82
The mother-daughter health collaborative: a partnership development to promote cancer education. J Cancer Educ (2010) 0.77
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med (2001) 4.68
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA (1992) 3.81
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV. Am J Epidemiol (1994) 2.81
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
Correlates of HIV infection among young adult short-term injection drug users. AIDS (2000) 2.63
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend (1995) 2.51
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Active management of labor as an alternative to cesarean section for dystocia. Obstet Gynecol (1984) 2.41
Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol (1997) 2.32
Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol (2003) 2.32
People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.26
Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis (1995) 2.25
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
Citizen action for environmental health: report on a survey of community organizations. Am J Public Health (1984) 2.11
Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med (1995) 2.08
Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. Am J Epidemiol (2007) 2.07
The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Am J Community Psychol (1996) 2.07
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction (1993) 2.01
Transmission of HIV-1 within a statewide prison system. AIDS (1988) 2.00
Reintegrating women leaving jail into urban communities: a description of a model program. J Urban Health (2001) 1.96
Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland. Infect Control Hosp Epidemiol (1995) 1.95
The impact of bronchial asthma on school attendance and performance. J Sch Health (1980) 1.91
Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev (1994) 1.87
The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun (2006) 1.85
Compliance with universal precautions among health care workers at three regional hospitals. Am J Infect Control (1995) 1.83
Gender differences in the initiation of injection drug use among young adults. J Urban Health (2000) 1.78
Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med (1993) 1.76
Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1991) 1.76
Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol (1997) 1.76
Syphilis serology in human immunodeficiency virus infection: evidence for false-negative fluorescent treponemal testing. J Infect Dis (1997) 1.74
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A (1998) 1.72
Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health (1999) 1.71
My place, your place, and no place: behavior settings as a risk factor for HIV-related injection practices of drug users in Baltimore, Maryland. Am J Community Psychol (1994) 1.71
Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS (2000) 1.70
Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis (1999) 1.69
Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health (1991) 1.68
Risk factors for shooting gallery use and cessation among intravenous drug users. Am J Public Health (1991) 1.66
Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol (1995) 1.65
Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem J (1999) 1.62
Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol (1994) 1.60
The relationship between risk networks' patterns of crack cocaine and alcohol consumption and HIV-related sexual behaviors among adult injection drug users: a prospective study. Drug Alcohol Depend (1996) 1.59
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med (1996) 1.59
Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol (1993) 1.59
Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr (1999) 1.57
Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend (2001) 1.57
Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol (2000) 1.57
Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. Br J Exp Pathol (1982) 1.54
Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis (1997) 1.54
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis (1996) 1.53
Measurement of HIV risk behaviors among intravenous drug users. Br J Addict (1992) 1.53
Selective risk taking among needle exchange participants: implications for supplemental interventions. Am J Public Health (2001) 1.52
New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol (1991) 1.52
The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health (1994) 1.52
Can HIV epidemics among injection drug users be prevented? AIDS (1998) 1.51
An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis (1996) 1.51
Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis (1999) 1.51
Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol (1993) 1.51
Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis (1999) 1.48
Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health (1999) 1.47
Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users. Drug Alcohol Depend (1994) 1.47
Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol (1998) 1.46
Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group. J Allergy Clin Immunol (1999) 1.46
Time for a national agenda to improve the health of urban populations. Am J Public Health (2000) 1.46
Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr (1992) 1.45
Drug abuse treatment success among needle exchange participants. Public Health Rep (1998) 1.45
A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun (1997) 1.44
Update on the seroepidemiology of human immunodeficiency virus in the United States household population: NHANES III, 1988-1994. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.44
Correlation of decrease in perinatal mortality and increase in cesarean section rates. Obstet Gynecol (1983) 1.43
Gender differences in injection-related behaviors among injection drug users in Baltimore, Maryland. AIDS Educ Prev (1998) 1.43
Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis (2003) 1.41
Inhibition of heme detoxification processes underlies the antimalarial activity of terpene isonitrile compounds from marine sponges. J Med Chem (2001) 1.41
Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA (1991) 1.39
Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med (1993) 1.39
Fast MR imaging of the liver: quantitative comparison of techniques. Radiology (1994) 1.38
Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV). J Infect Dis (1991) 1.37